AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1

Sitacip M 50/500 Tablet ER

Prescription Icon
Prescription Required

Marketer

Cipla Ltd

Salt Composition

Sitagliptin (50mg) + Metformin (500mg)

Overview Sitacip M 50/500 Tablet ER

Diabex Duo 50/500 Extended-Release tablets combine two medications to manage elevated blood glucose in type 2 diabetes patients. This dual action helps prevent serious diabetic complications like vision impairment and kidney disease, potentially lowering heart attack and stroke risk. Diabex Duo 50/500 ER might be used alone or with other anti-diabetic drugs, and is most effective with a balanced diet and regular physical activity. Dosage is personalized based on your health status, blood sugar readings, and current medications. Consuming it with food minimizes stomach upset. Consistent daily use, at the same time each day, maximizes benefits; discontinue only under your physician's guidance. Adherence to your prescribed diet and exercise plan is crucial for effective diabetes management. Common side effects include nausea, diarrhea, vomiting, stomach discomfort, headache, and throat irritation. Low blood sugar (hypoglycemia) is possible, especially with concurrent use of insulin or sulfonylureas; learn hypoglycemia recognition and management. This medication isn't suitable for everyone. Inform your doctor of any pre-existing kidney, liver, heart, or pancreatic conditions, or excessive alcohol consumption before starting. Pregnant or lactating individuals should consult their doctor. Interactions with other medications are possible; disclose all your medications for safety. Alcohol should be limited due to its blood glucose-lowering effect. Your doctor will monitor your kidney function and blood sugar levels throughout treatment.

Uses of Sitacip M 50/500 Tablet ER

Managing type 2 diabetes

Major Benefits of Sitacip M 50/500 Tablet ER:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the entire tablet without chewing, crushing, or breaking it. It's recommended to take Sitacip M 50/500 Tablet ER with a meal.

Common Side effects of Sitacip M 50/500 Tablet ER:

  • Decreased appetite
  • Vomiting
  • Upper respiratory tract infection
  • Hypoglycemia (low blood glucose level)
  • Abdominal bloating
  • Nausea
  • Diarrhea

How to use Sitacip M 50/500 Tablet ER:

Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Sitacip M 50/500 Tablet ER whole; avoid chewing, crushing, or breaking it. Administer this extended-release tablet with a meal.

How Sitacip M 50/500 Tablet ER works:

Sitagliptin and metformin, combined as Sitacip M 50/500 Extended-Release tablets, offer enhanced blood glucose management. Sitagliptin boosts insulin production by the pancreas, improves insulin utilization, and lessens hepatic glucose output. Metformin, a biguanide, reduces liver glucose production, slows intestinal glucose absorption, and enhances insulin sensitivity. This dual-action approach leads to superior glycemic control.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Sitacip M 50/500 Tablet ER and alcohol is strongly discouraged due to safety concerns.

PregnancyPregnancyCONSULT YOUR DOCTOR

The use of Sitacip M 50/500 Extended-Release Tablets during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the potential advantages against any possible risks prior to prescription. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Extended-release Sitacip M 50/500 tablets are likely unsuitable for breastfeeding mothers. Available human data indicates potential transfer to breast milk, posing a risk to the infant.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.

KidneyKidneyCAUTION

Patients with kidney impairment should use Sitacip M 50/500 ER tablets cautiously, potentially requiring dosage modification. Consultation with a physician is essential. For individuals with severe kidney disease, this medication is contraindicated. Kidney function should be regularly monitored during treatment.

LiverLiverUNSAFE

Extended-release Sitacip M 50/500 tablets are likely contraindicated for individuals with hepatic impairment and should be avoided. Medical advice is recommended.

What if you forget to take Sitacip M 50/500 Tablet ER :

Should you forget a dose of Sitacip M 50/500 Extended-Release Tablet, administer it promptly. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Sitacip M 50/500 Tablet ER

LabelValue
Developing Habits No.
Treatment Category Diabetes Management

FAQs on Sitacip M 50/500 Tablet ER

Sitacip M 50/500 ER tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This medication improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. It's not suitable for individuals under 18.
Prolonged use of Sitacip M 50/500 Tablet ER can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, urinary issues, cognitive changes, and ataxia), if left unaddressed. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Sitacip M 50/500 Tablet ER may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infection. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Patients with allergies to Sitacip M 50/500 Tablet ER components or excipients, or those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis should not use this medication.
Combining Sitacip M 50/500 Tablet ER with alcohol is unsafe and may heighten the risk of lactic acidosis.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Sitagliptin/Metformin (Sitacip M 50/500 Tablet ER) can cause lactic acidosis, a serious medical emergency resulting from excess blood lactic acid (also known as MALA, Metformin-associated lactic acidosis). This rare side effect necessitates avoiding the drug in patients with kidney disease, the elderly, or heavy alcohol users. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If these occur, discontinue Sitagliptin/Metformin and seek immediate medical attention.
Sitacip M 50/500 ER tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This medication improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. This combination is not suitable for individuals under 18.
Sitacip M 50/500 Tablet ER may cause common side effects such as hypoglycemia, taste changes, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Sitacip M 50/500 Tablet ER is contraindicated in patients with allergies to its components or excipients, and those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Sitacip M 50/500 Tablet ER with alcohol is unsafe and may heighten the risk of lactic acidosis.
Sitagliptin/Metformin (Sitacip M 50/500 Tablet ER) can cause lactic acidosis, a serious medical emergency resulting from excess blood lactic acid (also known as MALA, Metformin-associated lactic acidosis). This rare side effect necessitates caution in patients with kidney disease, the elderly, or those who consume excessive alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If experienced, discontinue Sitagliptin/Metformin and seek immediate medical attention.
Prolonged use of Sitacip M 50/500 Tablet ER can lead to vitamin B12 deficiency by hindering its absorption. This deficiency, if left untreated, may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, urinary issues, cognitive changes, and ataxia), necessitating supplemental vitamin B12 at least annually, as suggested by some researchers.
Store this medication in its original, tightly closed container, as directed on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Sitacip M 50/500 ER tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Sitacip M 50/500 Tablet ER may cause common side effects such as low blood sugar (hypoglycemia), taste changes, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use may also result in vitamin B12 deficiency.
Patients with known allergies to Sitacip M 50/500 Tablet ER components or excipients, or those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis should not use this medication.
Combining Sitacip M 50/500 Tablet ER with alcohol is unsafe and may heighten the risk of lactic acidosis.
Sitagliptin/Metformin (Sitacip M 50/500 Tablet ER) can cause lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also known as MALA, or Metformin-associated lactic acidosis). This rare side effect necessitates avoiding the drug in patients with kidney disease, the elderly, or those who consume significant alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. Should these symptoms appear, discontinue Sitagliptin/Metformin immediately and seek medical attention.
Prolonged use of Sitacip M 50/500 Tablet ER can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, urinary issues, cognitive changes, and ataxia), if left unaddressed. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Sitacip M 50/500 Tablet E...
103
MRP 120
14% off